Phenyl Benzenesulfonylhydrazides Exhibit Selective Indoleamine 2,3-Dioxygenase Inhibition with Potent in Vivo Pharmacodynamic Activity and Antitumor Efficacy

Journal of Medicinal Chemistry

Volumn 59, Issue 1, 2016, Pages 419-430

  Lin, Shu Yu ^a   Yeh, Teng Kuang ^a   Kuo, Ching Chuan ^a   Song, Jen Shin ^a   Cheng, Ming Fu ^a   Liao, Fang Yu ^a   Chao, Min Wu ^b   Huang, Han Li ^b   Chen, Yi Lin ^b   Yang, Chun Yu ^a   Wu, Mine Hsine ^a   Hsieh, Chia Ling ^a   Hsiao, Wenchi ^a   Peng, Yi Hui ^a   Wu, Jian Sung ^a   Lin, Li Mei ^a   Sun, Manwu ^a   Chao, Yu Sheng ^a   Shih, Chuan ^a   Wu, Su Ying ^a   Pan, Shiow Lin ^b   Hung, Ming Shiu ^a   Ueng, Shau Hua ^a   more..

^a NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

^b TAIPEI MEDICAL UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

1 ACETYL 2,3 DIHYDRO 1H INDOLE 5 SULFONYL CHLORIDE; 1 ACETYL N' (4 BROMOPHENYL) 2,3 DIHYDRO 1H INDOLE 5 SULFONYL HYDRAZIDE; 2 AMINO N' (4 BROMOPHENYL) 1H BENZIMIDAZOLE 5 SULFONYL HYDRAZIDE; 2 OXO 1,2 DIHYDRO 6 QUINOLINESULFONYL CHLORIDE; 2 OXO 1,2,3,4 TETRAHYDROQUINOLINE 6 SULFONYL CHLORIDE; 2 OXO 2,3 DIHYDRO 1H BENZIMIDAZOLE 5 SULFONYL CHLORIDE; 2 OXO 2,3 DIHYDRO 1H INDOLE 5 SULFONYL CHLORIDE; 2 OXO 2,3,4,5 TETRAHYDRO 1H 1 BENZAZEPINE 7 SULFONYL CHLORIDE; 2,3 DIOXO 2,3 DIHYDRO 1H INDOLE 5 SULFONYL CHLORIDE; 3,3 DIFLUORO 2 OXO 2,3 DIHYDRO 1H NDOLE 5 SULFONYL CHLORIDE; 3,3 DIMETHYL 2 OXO 2,3 DIHYDRO 1H INDOLE 5 SULFONYL CHLORIDE; 4 (2 OXOPYRROLIDIN 1 YL)BENZENESULFONYL CHLORIDE; ANTINEOPLASTIC AGENT; BENZENE DERIVATIVE; CYCLOPHOSPHAMIDE; HYDRAZIDE DERIVATIVE; INDOLEAMINE 2,3 DIOXYGENASE INHIBITOR; KYNURENINE; N' (4 BROMOPHENYL) 1 METHYL 2 OXO 2,3 DIHYDRO 1H INDOLE 5 SULFONYL HYDRAZIDE; N' (4 BROMOPHENYL) 1,3 DIMETHYL 2 OXO 2,3 DIHYDRO 1H BENZIMIDAZOLE 5 SULFONYL HYDRAZIDE; N' (4 BROMOPHENYL) 2 OXO 1,2,3,4 TETRAHYDROQUINOLINE 6 SULFONYL HYDRAZIDE; N' (4 BROMOPHENYL) 2 OXO 2,3 DIHYDRO 1H BENZIMIDAZOLE 5 SULFONYL HYDRAZIDE; N' (4 BROMOPHENYL) 2 OXO 2,3 DIHYDRO 1H INDOLE 5 SULFONYL HYDRAZIDE; N' (4 BROMOPHENYL) 2,3 DIOXO 2,3 DIHYDRO 1H INDOLE 5 SULFONOHYDRAZIDE; N' (4 BROMOPHENYL) 3,3 DIFLUORO 2 OXO 2,3 DIHYDRO 1H INDOLE 5 SULFONYL HYDRAZIDE; N' (4 BROMOPHENYL) 3,3 DIMETHYL 2 OXO 2,3 DIHYDRO 1H INDOLE 5 SULFONYL HYDRAZIDE; N' (4 BROMOPHENYL) 4 (2 OXOPYRROLIDIN 1 YL)BENZENESULFONYL HYDRAZIDE; PHENYL BENZENESULFONYL HYDRAZIDE; TRYPTOPHAN; UNCLASSIFIED DRUG; UNINDEXED DRUG; ENZYME INHIBITOR; INDOLEAMINE 2,3 DIOXYGENASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BECKMANN REARRANGEMENT; BODY WEIGHT; CANCER IMMUNOTHERAPY; CANCER INHIBITION; COLORECTAL CANCER; COLORECTAL TUMOR; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG HALF LIFE; DRUG POTENCY; DRUG SYNTHESIS; ENZYME ACTIVITY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LIQUID CHROMATOGRAPHY; MALE; MELANOMA; NONHUMAN; PROTEIN EXPRESSION; RAT; SINGLE DRUG DOSE; STEREOSPECIFICITY; TANDEM MASS SPECTROMETRY; TREATMENT DURATION; TRYPTOPHAN METABOLISM; WEIGHT REDUCTION; ANIMAL; ANTAGONISTS AND INHIBITORS; BAGG ALBINO MOUSE; BIOAVAILABILITY; C57BL MOUSE; DRUG DESIGN; DRUG SCREENING; METABOLISM; MOUSE; SPRAGUE DAWLEY RAT; STRUCTURE ACTIVITY RELATION; SYNTHESIS;

ANIMALS; ANTINEOPLASTIC AGENTS; BIOLOGICAL AVAILABILITY; DRUG DESIGN; ENZYME INHIBITORS; HUMANS; INDOLEAMINE-PYRROLE 2,3,-DIOXYGENASE; KYNURENINE; MALE; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; RATS; RATS, SPRAGUE-DAWLEY; STRUCTURE-ACTIVITY RELATIONSHIP; TRYPTOPHAN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84955140232     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/acs.jmedchem.5b01640     Document Type: Article

References (51)

1. Munn, D. H.; Mellor, A. L. Indoleamine 2,3 dioxygenase and metabolic control of immune responses Trends Immunol. 2013, 34, 137-143 10.1016/j.it.2012.10.001
2. van Baren, N.; Van den Eynde, B. J. Tryptophan-degrading enzymes in tumoral immune resistance Front. Immunol. 2015, 6, 34 10.3389/fimmu.2015.00034
3. Curti, A.; Trabanelli, S.; Salvestrini, V.; Baccarani, M.; Lemoli, R. M. The role of indoleamine 2,3-dioxygenase in the induction of immune tolerance: focus on hematology Blood 2009, 113, 2394-2401 10.1182/blood-2008-07-144485
4. Munn, D. H.; Sharma, M. D.; Baban, B.; Harding, H. P.; Zhang, Y.; Ron, D.; Mellor, A. L. GCN2 kinase in T cells mediates proliferative arrest and anergy induction in response to indoleamine 2,3-dioxygenase Immunity 2005, 22, 633-642 10.1016/j.immuni.2005.03.013
5. Sharma, M. D.; Baban, B.; Chandler, P.; Hou, D.-Y.; Singh, N.; Yagita, H.; Azuma, M.; Blazar, B. R.; Mellor, A. L.; Munn, D. H. Plasmacytoid dendritic cells from mouse tumor-draining lymph nodes directly activate mature Tregs via indoleamine 2,3-dioxygenase J. Clin. Invest. 2007, 117, 2570-2582 10.1172/JCI31911
6. Uyttenhove, C.; Pilotte, L.; Théate, I.; Stroobant, V.; Colau, D.; Parmentier, N.; Boon, T.; Van den Eynde, B. J. Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase Nat. Med. 2003, 9, 1269-1274 10.1038/nm934
7. Godin-Ethier, J.; Hanafi, L. A.; Piccirillo, C. A.; Lapointe, R. Indoleamine 2,3-dioxygenase expression in human cancers: clinical and immunologic perspectives Clin. Cancer Res. 2011, 17, 6985-6991 10.1158/1078-0432.CCR-11-1331
8. Muller, A. J.; DuHadaway, J. B.; Donover, P. S.; Sutanto-Ward, E.; Prendergast, G. C. Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy Nat. Med. 2005, 11, 312-319 10.1038/nm1196
9. Hou, D.-Y.; Muller, A. J.; Sharma, M. D.; DuHadaway, J. B.; Banerjee, T.; Johnson, M.; Mellor, A. L.; Prendergast, G. C.; Munn, D. H. Inhibition of indoleamine 2,3-dioxygenase in dendritic cells by stereoisomers of 1-methyl-tryptophan correlates with antitumor responses Cancer Res. 2007, 67, 792-801 10.1158/0008-5472.CAN-06-2925
10. Koblish, H. K.; Hansbury, M. J.; Bowman, K. J.; Yang, G.; Neilan, C. L.; Haley, P. J.; Burn, T. C.; Waeltz, P.; Sparks, R. B.; Yue, E. W.; Combs, A. P.; Scherle, P. A.; Vaddi, K.; Fridman, J. S. Hydroxyamidine inhibitors of indoleamine-2,3-dioxygenase potently suppress systemic tryptophan catabolism and the growth of IDO-expressing tumors Mol. Cancer Ther. 2010, 9, 489-498 10.1158/1535-7163.MCT-09-0628
11. Smith, C.; Chang, M. Y.; Parker, K. H.; Beury, D. W.; DuHadaway, J. B.; Flick, H. E.; Boulden, J.; Sutanto-Ward, E.; Soler, A. P.; Laury-Kleintop, L. D.; Mandik-Nayak, L.; Metz, R.; Ostrand-Rosenberg, S.; Prendergast, G. C.; Muller, A. J. IDO is a nodal pathogenic driver of lung cancer and metastasis development Cancer Discovery 2012, 2, 722-735 10.1158/2159-8290.CD-12-0014
12. Röhrig, U. F.; Majjigapu, S. R.; Vogel, P.; Zoete, V.; Michielin, O. Challenges in the Discovery of Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitors. J. Med. Chem. 2015, and references herein. DOI: 10.1021/acs.jmedchem.5b00326.
13. Dolušić, E.; Frédérick, R. Indoleamine 2,3-dioxygenase inhibitors: a patent review Expert Opin. Ther. Pat. 2013, 23, 1367-1381 and references herein. 10.1517/13543776.2013.827662
14. Austin, C. J.; Rendina, L. M. Targeting key dioxygenases in tryptophan-kynurenine metabolism for immunomodulation and cancer chemotherapy Drug Discovery Today 2015, 20, 609-617 and references herein. 10.1016/j.drudis.2014.11.007
15. Gaspari, P.; Banerjee, T.; Malachowski, W. P.; Muller, A. J.; Prendergast, G. C.; DuHadaway, J. B.; Bennett, S.; Donovan, A. M. Structure-activity study of brassinin derivatives as indoleamine 2,3-dioxygenase inhibitors J. Med. Chem. 2006, 49, 684-692 10.1021/jm0508888
16. Muller, A. J.; DuHadaway, J. B.; Donover, P. S.; Sutanto-Ward, E.; Prendergast, G. C. Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene bin1, potentiates cancer chemotherapy Nat. Med. 2005, 11, 312-319 10.1038/nm1196
17. Kumar, S.; Malachowski, W. P.; DuHadaway, J. B.; LaLonde, J. M.; Carroll, P. J.; Jaller, D.; Metz, R.; Prendergast, G. C.; Muller, A. J. Indoleamine 2,3-dioxygenase is the anticancer target for a novel series of potent naphthoquinone-based inhibitors J. Med. Chem. 2008, 51, 1706-1718 10.1021/jm7014155
18. Carr, G.; Chung, M. K. W.; Mauk, A. G.; Andersen, R. J. Synthesis of indoleamine 2,3-dioxygenase inhibitory analogues of the sponge alkaloid exiguamine A J. Med. Chem. 2008, 51, 2634-2637 10.1021/jm800143h
19. Jang, J.-P.; Jang, J.-H.; Oh, M.; Son, S.; Kim, S. M.; Kim, H.-M.; Shin, K.-S.; Oh, H.; Soung, N. K.; Hong, Y.-S.; Kim, B. Y.; Ahn, J. S. Inhibition of indoleamine 2,3-dioxygenase by thielavin derivatives from a soil fungus, Coniochaeta sp. 10F058 J. Antibiot. 2014, 67, 331-333 10.1038/ja.2013.134
20. Bridewell, D. J. A.; Sperry, J.; Smith, J. R.; Kosim-Satyaputra, P.; Ching, L.-M.; Jamie, J. F.; Brimble, M. A. Natural Product-Inspired Pyranonaphthoquinone Inhibitors of Indoleamine 2,3-Dioxygenase-1 (IDO-1) Aust. J. Chem. 2013, 66, 40-49 10.1071/CH12393
21. Pasceri, R.; Siegel, D.; Ross, D.; Moody, C. J. Aminophenoxazinones as Inhibitors of Indoleamine 2,3-Dioxygenase (IDO). Synthesis of Exfoliazone and Chandrananimycin A J. Med. Chem. 2013, 56, 3310-3317 10.1021/jm400049z
22. Yang, S.; Li, X.; Hu, F.; Li, Y.; Yang, Y.; Yan, J.; Kuang, C.; Yang, Q. Discovery of Tryptanthrin Derivatives as Potent Inhibitors of Indoleamine 2,3-Dioxygenase with Therapeutic Activity in Lewis Lung Cancer (LLC) Tumor-Bearing Mice J. Med. Chem. 2013, 56, 8321-8331 10.1021/jm401195n
23. Blunt, C. E.; Torcuk, C.; Liu, Y.; Lewis, W.; Siegel, D.; Ross, D.; Moody, C. J. Synthesis and Intracellular Redox Cycling of Natural Quinones and Their Analogues and Identification of Indoleamine-2,3-dioxygenase (IDO) as Potential Target for Anticancer Activity Angew. Chem., Int. Ed. 2015, 54, 8740-8745 10.1002/anie.201503323
24. Kumar, S.; Jaller, D.; Patel, B.; LaLonde, J. M.; DuHadaway, J. B.; Malachowski, W. P.; Prendergast, G. C.; Muller, A. J. Structure based development of phenylimidazole-derived inhibitors of indoleamine 2,3-dioxygenase J. Med. Chem. 2008, 51, 4968-4977 10.1021/jm800512z
25. Huang, Q.; Zheng, M.; Yang, S.; Kuang, C.; Yu, C.; Yang, Q. Structure-activity relationship and enzyme kinetic studies on 4-aryl-1H-1,2,3-triazoles as indoleamine 2,3-dioxygenase (IDO) inhibitors Eur. J. Med. Chem. 2011, 46, 5680-5687 10.1016/j.ejmech.2011.08.044
26. Röhrig, U. F.; Majjigapu, S. R.; Grosdidier, A.; Bron, S.; Stroobant, V.; Pilotte, L.; Colau, D.; Vogel, P.; Van den Eynde, B. J.; Zoete, V.; Michielin, O. Rational design of 4-aryl-1,2,3-triazoles for indoleamine 2,3-dioxygenase 1 inhibition J. Med. Chem. 2012, 55, 5270-5290 10.1021/jm300260v
27. Dolušić, E.; Larrieu, P.; Blanc, S.; Sapunaric, F.; Norberg, B.; Moineaux, L.; Colette, D.; Stroobant, V.; Pilotte, L.; Colau, D.; Ferain, T.; Frasr, G.; Galeni, M.; Frère, J.-M.; Masereel, B.; Van den Eynde, B.; Wouters, J.; Frédérick, R. Indol-2-yl ethanones as novel indoleamine 2,3-dioxygenase (IDO) inhibitors Bioorg. Med. Chem. 2011, 19, 1550-1561 10.1016/j.bmc.2010.12.032
28. Roehrig, U.; Loay, A.; Michielin, O.; Van den Eynde, B.; Pilotte, L.; Stroobant, V.; Larrieu, P. IDO Inhibitors and Therapeutic Uses Thereof. Patent WO2009/127669, 2009.
29. Matsuno, K.; Yamazaki, H.; Isaka, Y.; Takai, K.; Unno, Y.; Ogo, N.; Ishikawa, Y.; Fujii, S.; Takikawa, O.; Asai, A. Novel candesartan derivatives as indoleamine 2,3-dioxygenase inhibitors MedChemComm 2012, 3, 475-479 10.1039/c2md00278g
30. Yue, E. W.; Douty, B.; Wayland, B.; Bower, M.; Liu, X.; Leffet, L.; Wang, Q.; Bowman, K. J.; Hansbury, M. J.; Liu, C.; Wei, M.; Li, Y.; Wynn, R.; Burn, T. C.; Koblish, H. K.; Fridman, J. S.; Metcalf, B.; Scherle, P. A.; Combs, A. P. Discovery of potent competitive inhibitors of indoleamine 2,3-dioxygenase with in vivo pharmacodynamic activity and efficacy in a mouse melanoma model J. Med. Chem. 2009, 52, 7364-7367 10.1021/jm900518f
31. Tao, M.; Frietze, W.; Meloni, D. J.; Weng, L.; Zhou, J.; Pan, Y. Process for the Synthesis of an Indoleamine 2,3-Dioxygenase Inhibitor. Patent WO2015/070007, 2015.
32. Matsuno, K.; Takai, K.; Isaka, Y.; Unno, Y.; Sato, M.; Takikawa, O.; Asai, A. S-benzylisothiourea derivatives as small-molecule inhibitors of indoleamine-2,3-dioxygenase Bioorg. Med. Chem. Lett. 2010, 20, 5126-5129 10.1016/j.bmcl.2010.07.025
33. Meininger, D.; Zalameda, L.; Liu, Y.; Stepan, L. P.; Borges, L.; McCarter, J. D.; Sutherland, C. L. Purification and kinetic characterization of human indoleamine 2,3-dioxygenase 1 and 2 (IDO1 and IDO2) and discovery of selective IDO1 inhibitors Biochim. Biophys. Acta, Proteins Proteomics 2011, 1814, 1947-1954 10.1016/j.bbapap.2011.07.023
34. Tojo, S.; Kohno, T.; Tanaka, T.; Kamioka, S.; Ota, Y.; Ishii, T.; Kamimoto, K.; Asano, S.; Isobe, Y. Crystal structures and structure-activity relationships of imidazothiazole derivatives as IDO1 inhibitors ACS Med. Chem. Lett. 2014, 5, 1119-1123 10.1021/ml500247w
35. See https://www.clinicaltrials.gov/.
36. Mautino, M.; Kumar, S.; Waldo, J.; Jaipuri, F.; Kesharwani, T. Fused Imidazole Derivatives Useful as IDO Inhibitors. Patent WO2012/142237, 2012.
37. Kumar, S.; Waldo, J.; Jaipuri, F.; Mautino, M. Tricyclic Compounds as Inhibitors of Immunosuppression Mediated by Tryptophan Metabolization. Patent WO2014/159248, 2014.
38. Balog, J. A.; Huang, A.; Chen, B.; Chen, L.; Shan, W. IDO Inhibitors. Patent WO2014/150646, 2014.
39. Balog, J. A.; Huang, A.; Chen, B.; Chen, L.; Seitz, S. P.; Hart, A.; Markwalder, J. A. Inhibitors of Indoleamine 2,3-Dioxygenase (IDO). Patent WO2014/150677, 2014.
40. Markwalder, J. A.; Seitz, S. P.; Balog, J. A.; Huang, A.; Mandal, S. K.; Williams, D. K.; Hart, A.; Inghrim, J. IDO Inhibitors. Patent WO2015/002918, 2015.
41. Markwalder, J. A.; Balog, J. A.; Huang, A.; Seitz, S. P. IDO Inhibitors. Patent WO2015/006520, 2015.
42. Markwalder, J. A.; Seitz, S. P.; Balog, J. A.; Huang, A.; Williams, D. K.; Chen, L.; Mandal, S. K. IDO Inhibitors. Patent WO2015/031295, 2015.
43. Banerjee, M.; Middya, S.; Shrivastava, R.; Raina, S.; Surya, A.; Yadav, V. K.; Kapoor, K. K. Aminonitriles as Kynurenine Pathway Inhibitors. Patent WO2014/141110, 2014.
44. Banerjee, M.; Middya, S.; Shrivastava, R.; Raina, S.; Surya, A.; Yadav, D. B.; Yadav, V. K.; Kapoor, K. K.; Venkatesan, A.; Smith, R. A.; Thompson, S. K. Inhibitors of the Kynurenine Pathway. Patent WO2014/186035, 2014.
45. Boyall, D.; Davis, C.; Dodd, J.; Everitt, S.; Miller, A.; Weber, P.; Westcott, J.; Young, S. Compounds Useful as Inhibitors of Indoleamine 2,3-Dioxygenase. Patent WO2014/081689, 2014.
46. Cowley, P.; Wise, A. Pharmaceutical Compound. Patent WO2015/082499, 2015.
47. Cheng, M. F.; Hung, M. S.; Song, J. S.; Lin, S. Y.; Liao, F. Y.; Wu, M. H.; Hsiao, W.; Hsieh, C. L.; Wu, J. S.; Chao, Y. S.; Shih, C.; Wu, S. Y.; Ueng, S. H. Discovery and structure-activity relationships of phenyl benzenesulfonylhydrazides as novel indoleamine 2,3-dioxygenase inhibitors Bioorg. Med. Chem. Lett. 2014, 24, 3403-3406 10.1016/j.bmcl.2014.05.084
48. Zhao, N.; Li, Y.; Wang, Y.; Wang, J. A facile and efficient synthesis of aryl toluenesulfonhydrazides and aryl toluenesulfonates under solvent-free conditions J. Sulfur Chem. 2006, 27, 427-432 10.1080/17415990600863752
49. Leban, J.; Pegoraro, S.; Dormeyer, M.; Lanzer, M.; Aschenbrenner, A.; Kramer, B. Sulfonyl-phenyl-ureido benzamidines: a novel structural class of potent antimalarial agents Bioorg. Med. Chem. Lett. 2004, 14, 1979-1982 10.1016/j.bmcl.2004.01.083
50. Lin, P.; Chang, L.; Edmondson, S. D. Pyrrolidine-Derived Beta 3 Adrenergic Receptor Agonists. Patent WO2010/129326, 2015.
51. Gowda, B. T.; Foro, S.; Nirmala, P. G.; Fuess, H. N-(2,4-Dichlorophenyl)benzenesulfonamide Acta Crystallogr., Sect. E: Struct. Rep. Online 2010, E66, o229 10.1107/S160053680905452X